SciELO - Scientific Electronic Library Online

vol.24 suppl.1Manejo de los casos en retratamiento de tuberculosis con sospecha de resistencia a fármacos author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google



Print version ISSN 0120-4157
On-line version ISSN 2590-7379


GARCIA, Luis F  and  BARRERA, Luis F. Perspectivas para nuevas vacunas antituberculosas en la era posgenómica. Biomédica [online]. 2004, vol.24, suppl.1, pp.228-238. ISSN 0120-4157.

Perspectives for new anti-tuberculous vaccines in the post-genomic era Vaccination with attenuated Mycobacterium bovis BCG has been used as the routine procedure to immunize against tuberculosis. Since the efficacy of BCG vaccination is very controversial, the search for new immunoprophylatic tools against tuberculosis is an area of intense interest. Knowledge of the complete sequence of Mycobacterium tuberculosis (Mtb) H37Rv genome and the application of new immunological, biochemical and genetic technologies has led to a detailed understanding of the transcriptome and proteome of this bacterium. Approximately one-third of the human population is infected with Mtb; however, the bacillus is only detected once the symptoms appear and therefore most of the recent efforts have been devoted to the development of a post-infection vaccine. In theory, this vaccine (1) will give rise to an increase in the long-lasting specific immunity against Mtb, (2) will not have significant adverse effects, and (3) will be affordable for the people in third world countries. The main strategies that have been developed include the subunit vaccines, either as a mixture of relevant immunogenic proteins or DNA constructs, recombinant strains of Mycobacterium bovis BCG and Mtb, designed to secrete immunogenic proteins or with attenuated virulence, respectively, and DNA-based vaccines. The subunit vaccines are delivered either as mixtures of immunogenic proteins and adjuvants, or as naked DNA or by viral vectors in order to induce a potent Th1 response. Most of these vaccines have been tested in several kinds of animal models, but they do not fully reproduce the human pathology. However, the results obtained so far are very encouraging and have led to the development of phase I trials in humans.

Keywords : tuberculosis; vaccines; Mycobacterium tuberculosis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License